Correction: Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries

Lauper K, Mongin D, Iannone F, *et al.* Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. *RMD Open* 2018;4:e000809. doi: 10.1136/rmdopen-2018-000809.

The article has been corrected since it was published online. The values in the second row “Total patient-years” of table 1 have been amended and the supplement file has been updated to support the same.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) [year]. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

RMD Open 2019;5:e000809corr1. doi:10.1136/rmdopen-2018-000809corr1